Posted on

Oral Antivirals Could Transform the Treatment of COVID-19

external content.duckduckgo 31

the staff of the Ridgewood blog

Ridgewood NJ, Oral antivirals could transform the treatment of COVID-19, allowing some patients to take medicines while recovering at home instead of having to visit health clinics or be admitted to hospital to receive injections or infusions of currently available therapies. Pfizer this morning released final analysis of its oral antiviral candidate PAXLOVID (the protease inhibitors nirmatrelvir and ritonavir, taken together), showing the treatment retained its 89% efficacy in preventing hospitalization and death among 2,246 high-risk COVID-19 patients.

Continue reading Oral Antivirals Could Transform the Treatment of COVID-19

Posted on

Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19

303 main

the staff of the Ridgewood blog

FOSTER CITY Calif,  Gilead Sciences, Inc. (Nasdaq: GILD) today announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 (novel coronavirus). These randomized, open-label, multicenter studies will enroll approximately 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, beginning in March. The studies will assess two dosing durations of remdesivir, administered intravenously. The initiation of these studies follows the U.S. Food and Drug Administration’s (FDA) rapid review and acceptance of Gilead’s investigational new drug (IND) filing for remdesivir for the treatment of COVID-19.

Continue reading Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19